CAG
RPRX icon

Csenge Advisory Group’s Royalty Pharma RPRX Stock Holding History

Csenge Advisory Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$273K Sell
5,699
-182
-3% -$7.97K 0.01% 598
2025
Q4 		$227K Sell
5,881
-232
-4% -$8.85K 0.01% 658
2025
Q3 		$216K Buy
+6,113
New +$221K 0.01% 642

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Csenge Advisory Group's RPRX Position: Q1 2026 in Review

Csenge Advisory Group reduced its Royalty Pharma (RPRX) stake by 3.1% in Q1 2026, selling an estimated $7.97K and leaving 5,699 shares worth $273K. The position accounts for 0.01% of the portfolio, ranked #598.

Csenge Advisory Group first reported a position in RPRX in Q3 2025 and has held it in 3 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Csenge Advisory Group held 5,699 shares of Royalty Pharma worth $273K as of Q1 2026.
  • Csenge Advisory Group sold 182 Royalty Pharma shares in Q1 2026, an estimated $7.97K.
  • Royalty Pharma made up 0.01% of Csenge Advisory Group's portfolio in Q1 2026, its #598 holding.
  • Csenge Advisory Group first reported a position in Royalty Pharma in Q3 2025 and has held it in 3 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Csenge Advisory Group's 13F filing for Q1 2026, filed 30 Apr 2026.